We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMothercare Regulatory News (MTC)

Share Price Information for Mothercare (MTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.00
Bid: 5.50
Ask: 6.50
Change: 0.25 (4.35%)
Spread: 1.00 (18.182%)
Open: 5.75
High: 0.00
Low: 0.00
Prev. Close: 5.75
MTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-close Trading Update

4 May 2023 07:00

Pre-close Trading Update

Mothercare plc

Pre-close trading update

Mothercare plc ("Mothercare" or "the Company"), the global specialist brand for parents and young children, today issues a pre-close trading update for the financial year ended 25 March 2023 (“FY23”). This update is based upon draft figures pending finalisation of the year end audit.

Highlights

Unaudited net worldwide retail sales by franchise partners of £322 million for the year, includes no contribution from the Russian market, which was suspended at the end of our previous financial year, representing an increase of 8% in continuing markets.Adjusted EBITDA of £6.5 to £7 million for FY23, ahead of analysts’ expectations Net debt of £12.3 million at the year endPension scheme deficit materially reduced to £39 million (March 2020: £124.6 million, March 2022 £78 million)

EBITDA before adjusting items is now expected in the range of £6.5 to £7 million for the financial year to 25 March 2023. For the prior year to March 2022 our Russian territory directly contributed some £5.5 million to our adjusted EBITDA, which coupled with some margin benefit due to shipping delays in last year’s results, means there is a year on year improvement in the underlying profitability of the business, once these elements are excluded.

Unaudited net worldwide retail sales by franchise partners were £322 million, compared to £385 million for the previous financial year which included £88 million from Russia. Hence total retail sales for the year to March 2023 were 8% higher than the levels for the previous financial year with the Russian retail sales excluded. Excluding our Middle East markets, as well as Russia, the increase was 17% and our Middle East markets (43% of our total retail sales) reduced by 1%, with Saudi Arabia weakest of these markets reflecting certain local factors some of which are transitory. As previously reported, in many of our territories our partners still need to clear old inventory due to the suppressed demand during Covid-19. These factors will continue to impact the Group results for the financial year to March 2024, which will defer previously anticipated growth notwithstanding ongoing improvements in product and service.

Our medium-term guidance is unchanged for the steady state operation in more normal circumstances and we believe our continuing franchise operations remain capable of exceeding £10 million operating profit and we are now focused on accelerating our growth in both existing and new markets.

Financing

At the year-end Mothercare had total cash of £7.2 million (March 2022: £9.2 million), reflecting ongoing tight control of cash, against the £19.5 million (March 2022: £19.1 million) of the Group’s existing loan facility, which remained fully drawn across the year.

With recent increases in interest rates, the interest rate on this loan is currently approximately 18.2%, which coupled with the extended time to return to pre-pandemic retail sales levels, particularly in our Middle Eastern markets, highlighted above, means the Board’s current forecasts for continuing operations show the Group may require waivers to future periods’ covenant tests. We have therefore commenced refinancing discussions with our lender to vary, renegotiate or refinance this debt facility. Additionally we are looking at various financing alternatives (including equity and equity linked structures) to give us both additional flexibility and reduced cash financing costs. For the avoidance of doubt the Group does not require (and is not seeking through this refinancing) additional liquidity.

Pension Schemes

The last full actuarial valuation of the schemes was at 31 March 2020 and showed a deficit of £124.6 million. The Trustees are currently undertaking a triennial actuarial valuation as at 31 March 2023, the results of which will be available later this year. As part of this valuation, the Trustees will review the assumptions used to determine the liabilities, including the mortality assumption. Recent mortality experience for the UK suggests that longevity improvements are not as high as previously expected and this is generally leading to a reduction in pension scheme liabilities. The latest analysis of the pension schemes, including an adjustment for the expected reduction in life expectancies, suggests a deficit of approximately £39 million at 31 March 2023 resulting from total assets at £198 million and total liabilities of £237 million. The results of the formal valuations currently underway may materially differ once the Trustees have completed their assessment.

The current recovery plan is based on the deficit at March 2022 of £78 million with annual contributions for the years ending in March of: 2024 - £4 million; 2025 - £7 million; 2026 - £8 million; 2027 to 2032 - £9 million; 2033 - £0.7 million. These contributions will be reviewed once the actuarial valuation as at 31 March 2023 is completed. Additionally, the Trustees in determining the amount of ongoing cash contributions, recognise the current level of borrowings and would be prepared to look afresh at the valuation assumptions if the covenant improves after the valuation date, for example via an equity linked structure, which could reduce the deficit further.

Clive Whiley, Chairman of Mothercare, commented:

“Once again our results demonstrate the resilience we have introduced to the business over recent years, where we continue to generate both profit and cash. This would not have been possible without the support of all of our colleagues, franchisees and manufacturing partners whom I would like to thank on behalf of the board.

Although our immediate priority remains to support our franchise partners as they emerge from a period of suppressed demand, ultimately for the benefit of our own business, we have also redoubled our efforts to restore critical mass.

Accordingly we are engaged in discussions to drive the Mothercare brand globally by widening the bandwidth of our product offering, alongside penetration into new territories via a variety of routes to market.”

Investor and analyst enquiries to:

Mothercare plc

Email: investorrelations@mothercare.com

Clive Whiley, Chairman

Andrew Cook, Chief Financial Officer

Numis (Nominated Advisor & Joint Corporate Broker)

Tel: 020 7260 1000

Luke Bordewich

Henry Slater

finnCap (Joint Corporate Broker)

Tel: 020 7220 0500

Christopher Raggett

MHP

Tel: 020 3128 8789

Email: mothercare@mhpc.com

Simon Hockridge

Tim Rowntree

Date   Source Headline
13th Mar 20247:50 amGNWBlock listing Interim Review
6th Dec 20239:32 amGNWHolding(s) in Company
28th Nov 202310:13 amGNWHolding(s) in Company
24th Nov 20237:00 amRNSInterim Results
23rd Oct 20231:43 pmGNWAGM Statement
25th Sep 20239:15 amGNWDirector/PDMR Shareholding
25th Sep 20237:00 amGNWAnnual Report and Accounts and Notice of AGM
22nd Sep 202312:33 pmGNWDirector/PDMR Shareholding
22nd Sep 20237:00 amRNSFull Year Results 2023
13th Sep 20237:19 amGNWBlock listing Interim Review
4th Jul 20239:43 amGNWHolding(s) in Company
9th Jun 20237:00 amGNWDirectorate change
4th May 20237:00 amGNWPre-close Trading Update
27th Mar 20238:06 amGNWDirector/PDMR Shareholding
13th Mar 20238:00 amGNWBlock listing Interim Review
2nd Mar 20234:35 pmRNSPrice Monitoring Extension
8th Feb 202310:45 amRNSDirector/PDMR Shareholding
3rd Feb 20234:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20239:00 amRNSDirector/PDMR Shareholding
23rd Dec 20227:00 amRNSFurther re: Appointment of Chief Executive Officer
15th Dec 20224:40 pmRNSSecond Price Monitoring Extn
15th Dec 20224:35 pmRNSPrice Monitoring Extension
24th Nov 20227:00 amRNSInterim results announcement
24th Nov 20227:00 amGNWAppointment of Chief Executive Officer
21st Nov 20224:36 pmRNSPrice Monitoring Extension
13th Oct 202212:38 pmGNWAGM Statement
16th Sep 20228:04 amGNWAnnual Report and Accounts and Notice of AGM
14th Sep 20221:31 pmGNWDirector/PDMR Shareholding
13th Sep 20224:40 pmRNSSecond Price Monitoring Extn
13th Sep 20224:35 pmRNSPrice Monitoring Extension
13th Sep 20224:12 pmGNWBlock listing Interim Review
13th Sep 20223:38 pmRNSFull Year Results 2022
16th May 20224:41 pmRNSSecond Price Monitoring Extn
16th May 20224:35 pmRNSPrice Monitoring Extension
4th May 20224:40 pmRNSSecond Price Monitoring Extn
4th May 20224:36 pmRNSPrice Monitoring Extension
11th Apr 20227:00 amGNWPre-close Trading Update
14th Mar 20229:12 amGNWBlock listing Interim Review
9th Mar 20227:00 amRNSStatement re Russia
24th Feb 20223:36 pmGNWHolding(s) in Company
24th Feb 202212:38 pmGNWHolding(s) in Company
4th Jan 20228:42 amGNWHolding(s) in Company
25th Nov 20217:00 amRNSInterim results announcement
27th Oct 202110:52 amGNWHolding(s) in Company
13th Sep 20218:15 amGNWBlock listing Interim Review
9th Sep 202111:49 amGNWAGM Statement and trading update
7th Sep 20217:10 amGNWHolding(s) in Company
10th Aug 202111:30 amGNWNotice of Annual General Meeting and Annual Report and Accounts
3rd Aug 20214:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.